

**BD (BDX) Valuation - Group 23****Table of Contents:**

Sheet 1: Assumptions Explanation  
Sheet 2: Inputs  
Sheet 3: Historical Analysis  
Sheet 4: Revenue Model  
Sheet 5: DCF Valuation  
Sheet 6: Comparables  
Sheet 7: BD Debt  
Sheet 8: Cost of Debt  
Sheet 9: Cost of Equity  
Sheet 10: WACC  
Sheet 11-14: BD Financials

**Analysts:**

Arisa Akiyama 1005763238  
Sahand Davari 1007130230  
Majd Hijazi 1005691020  
Victoria Magowan 1005152521  
Zhenyu Wang 1007072089  
Yuchen Zhang 1005727830

**Ref. # Explanation of Assumption**

- 1 The revenue growth rate is based on each segment's historical growth rate subject to adjustments based on current market conditions and future prospects.
- 2 COGS as % of revenue is used in our model since it is relatively stable over the years and it is highly correlated with revenue. There are significant inflation pressures which are expected to increase the prices of raw materials. It is also stated in BD's 2021 Annual Report that costs of raw materials, transportation, construction and other necessary costs for production and distribution of products have increased significantly. These pressures on its supply chain are expected to continue to increase. Therefore, we have adjusted the COGS as a % of revenue to be 3% higher than the historical average from 2016-2021. (BD Annual Report 2021 page 15)
- 3 OpEx as % of revenue is used in our model since it is relatively stable over the years and it is highly correlated with revenue. We then adjusted the cost to be a higher percentage as BD's costs are anticipated to increase. Firstly, the EU has recently adopted the EU Medical Device Regulation and the In Vitro Diagnostic Regulation which impose strict requirements for the marketing and sale of medical devices. Compliance and maintenance of medical devices subject to these regulations will increase operating expenses (BD Annual Report 2021 page 18). As mentioned in assumption 2, BD is subject to high inflation pressures which are expected to increase its operating expenses. In addition, the higher transportation and shipping costs as outlined in assumption 2 are expected to increase selling and administrative expenses. Overall, to account for these inflationary pressures on BD's costs, we have increased the OpEx as a % of revenues by 4% compared to the historical average.
- 4 D&A as % of revenue is used in our model since it is relatively stable over the years and D&A has a higher correlation with revenue compared to Net PPE.
- 5 Statutory US tax rate in 2021 is 21%.
- 6 The effective tax rate is much lower than federal statutory tax rate each year due to different foreign income tax on its foreign income (See BD Annual Report 2021 Note 16 - Income Taxes pg 99 and BD Annual Report 2018 Note 16 - Income Taxes pg 97). Since there is very high variability in the effective tax rate and we cannot reasonably predict the changes in the tax rates for each foreign country that BD operates in, we assume the US statutory tax rate of 21%.
- 7 It is more reasonable to use change in NWC as a % of revenue since the annual growth rate is very volatile with a high standard deviation.
- 8 CAPEX as % of revenue is used in our model since it is relatively stable over the years and it is highly correlated with revenue. We increased CAPEX as a % of revenue by 2% of the previous year as the CAPEX has been increasing each year from 2016 to 2021, with the exception of 2020 which was affected by the COVID-19 pandemic. Furthermore, management has expressed its strategy of geographic expansion which supports our assumption. (BD Annual Report 2021 page 39)
- 9 Increased revenue growth by .25 percentage points in bull case supported by an increase in the aging baby boomer population, an increase in chronic disease prevalence, and an assumed increase in elective procedures as virus eliminates all increasing demand.
- 10 COGS as % of revenue in the Bull case is decreased by 1 percentage point as supported in the company successfully cutting manufacturing and supplier costs.
- 11 OpEx as a % of revenue in the Bull case decreases by 1 percentage point as supported in successfully cutting operational expenses.
- 12 We assume that D&A as a % of revenue decreases in the Bull case by one percentage point.
- 13 We assume that CAPEX as a % of revenue in the Bull case decreases by 0.2 percentage points. We adjust for a small decrease as we believe that it is unlikely that the firm will decrease capital expenditures based on its increased spending on capital expenditures in the past few years.
- 14 We assume that net working capital as % of revenue increases by 0.5 percentage points in the Bull case.
- 15 Effective tax rate decreases in the Bull case to account for possible decrease compared to the statutory rate, especially due to foreign tax rate fluctuations.
- 16 Revenue growth decreases in Bear market as explained potentially due to maturing product lines and inability of company to continually reinnovate.
- 17 Increased COGS as % of revenue in Bear case by 3 percentage points relating to increased supply chain challenges, higher shipping costs, and cost inflation.
- 18 Increasing OPEX as % of revenue in Bear case due to continued inflation, higher supply chain challenges, and higher shipping costs.
- 19 D&A as a % of revenue increases in Bear case as the company is investing in fixed assets as seen in the cash flow statement.
- 20 We assume in the Bear case that capital expenditures as % of revenue increases by 2 percentage points as it is probable that capital expenditures will increase based on the historical trend of increased capital expenditures over the years.
- 21 In the Bear case, we assume that the change in NWC as % of revenue decreases by 0.5 percentage points.
- 22 In the Bear case, effective tax rate increases to account for possible increase compared to the statutory rate, especially due to foreign tax rate fluctuations.
- 23 BD has announced that it will spin-off the Diabetes Care Unit which produced \$1.16 billion in revenue in FY2021 (BD Annual Report 2021 page 27). We adjust the revenue of FY2022 down by the same amount multiplied by the average annual growth rate of the past 5 years to arrive at a negative annual growth rate for the year. The average of the past five year's annual revenue growth rate is used as the base for our projections of the annual growth rate in the next four years and it is multiplied by ratio of all of the other revenues excluding the Diabetes Care unit over the total revenues in the Medical Segment in 2021 to account for a lower growth due to the loss of the unit (BD Annual Report 2021 page 27). We did not adjust for COVID-19 impacts on revenues as the decrease in the growth rate in FY2020 due to COVID-19 related pressures is offset by the increase in the growth rate in FY2021.
- 24 The BD Life Sciences Segment experienced tremendous growth in revenues in FY2021 largely due to its COVID testing systems. The FY2022 is adjusted down to be the historical growth rate as demand for testing kits is expected to decrease as the pandemic conditions are anticipated to improve. We then further decreased the growth rate in FY2022 by 5% due to a product recall of Alaris which accounts for a large portion of the Medical Segment revenues. Although the liabilities incurred from the recall are only around \$156 million with respect to remediation costs (BD Annual Report 2021 page 28), we assume that there will be lost sales due to its impact on customer perception and decreased ESG reporting score. The FY2023, FY2024, FY2025 and FY2026 annual growth rates take the average of the growth rates from FY2017-FY2020, which excludes the high demand in FY2021, and is further adjusted downward to account for the Alaris product recall (BD Annual Report 2021 pg. 21).
- 25 For the BD Interventional Segment, the average of the historical annual revenue growth rate is used as the base for our projections of the annual growth rate in the next five years. However, we remove the annual growth rate in 2019 as it reflects an inflated increase due to the inclusion of revenues from a new acquisition (BD Annual Report 2019 page 28). We believe this segment will continue to grow as the company has invested a consistent amount as capital expenditures into this segment with \$120 million, \$119 million, and \$125million in FY2019, FY2020, and FY2021 respectively (BD Annual Report 2021 page 76). We did not adjust for COVID-19 impacts on revenues as the decrease in the growth rate in 2020 due to COVID-19 related pressures is offset by the increase in the growth rate in FY2021.
- 26 We assumed that the terminal growth rate is 2% with a conservative estimate aligned with the target inflation rate of the Federal Reserve . This is below the historical average GDP growth rate of around 3.14% from 1948 until 2021.
- 27 Since the cash flows are discounted to the fiscal year end of the company of September 31, 2021 under our DCF model, we adjust the discounted time period to discount back to January 24, 2022.
- 28 Located comparable companies through Factset, filtering through General Medical Devices in the North American region, with market caps over 10,000,000
- 29 Benchmark 10 year American treasury yield as of March 25th, 2022. (see screenshot below)
- 30 Risk premium in the US has an average of 5.5% in 2021, where the historical average has been between 5.2%-5.7%. Thus, we believe that a 5.5% estimate is reasonable.

[https://ycharts.com/indicators/us\\_inflation\\_rate](https://ycharts.com/indicators/us_inflation_rate)

<https://tradingeconomics.com/united-states/gdp-growth-annual#:~:text=GDP%20Annual%20Growth%20Rate%20in,the%20second%20quarter%20of%202020>

<https://www.bloomberg.com/markets/rates-bonds/government-bonds/us>

<https://www.statista.com/statistics/664840/average-market-risk-premium-usa/#:~:text=The%20average%20market%20risk%20premium,and%205.7%20percent%20since%202011>

Case Number	1	*Linked to "DCF Valuation"
-------------	---	----------------------------

Case Guide	
1	Base
2	Bull
3	Bear

Selected: Base Case	FY2016A	FY2017A	FY2018A	FY2019A	FY2020A	FY2021A	FY2022E	FY2023E	FY2024E	FY2025E	FY2026E
Revenue Growth	0.00%	-3.12%	32.17%	8.18%	-1.00%	18.29%	-1.72%	3.17%	3.19%	3.20%	3.22%
COGS as a % of Revenue	43.60%	43.10%	42.91%	39.75%	43.87%	42.66%	45.65%	45.65%	45.65%	45.65%	45.65%
OpEx as a % of Revenue	30.71%	30.59%	31.41%	31.20%	31.67%	30.65%	35.04%	35.04%	35.04%	35.04%	35.04%
D&A as a % of Revenue	8.41%	7.76%	11.61%	12.32%	11.86%	10.54%	10.42%	10.42%	10.42%	10.42%	10.42%
CAPEX as a % of Revenue	5.75%	6.01%	5.60%	5.53%	4.73%	6.08%	6.62%	7.62%	8.62%	9.62%	10.62%
Change in NWC as % of Revenue	3.20%	-3.07%	5.61%	-2.13%	0.66%	1.65%	0.99%	0.99%	0.99%	0.99%	0.99%
Effective Tax Rate	9.12%	-12.70%	73.49%	-4.85%	11.27%	6.69%	21.00%	21.00%	21.00%	21.00%	21.00%

[Assumption 2](#)
[Assumption 3](#)
[Assumption 4](#)
[Assumption 8](#)
[Assumption 7](#)
[Assumption 6](#)

Base Case	FY2016A	FY2017A	FY2018A	FY2019A	FY2020A	FY2021A	FY2022E	FY2023E	FY2024E	FY2025E	FY2026E	
Revenue Growth		-3.12%	32.17%	8.18%	-1.00%	18.29%	-1.72%	3.17%	3.19%	3.20%	3.22%	*See tab "Revenue Model" for assumptions
COGS as a % of Revenue	43.60%	43.10%	42.91%	39.75%	43.87%	42.66%	45.65%	45.65%	45.65%	45.65%	45.65%	*See tab "Historical Analysis" for assumptions
OpEx as a % of Revenue	30.71%	30.59%	31.41%	31.20%	31.67%	30.65%	35.04%	35.04%	35.04%	35.04%	35.04%	*See tab "Historical Analysis" for assumptions
D&A as a % of Revenue	8.41%	7.76%	11.61%	12.32%	11.86%	10.54%	10.42%	10.42%	10.42%	10.42%	10.42%	*See tab "Historical Analysis" for assumptions
CAPEX as a % of Revenue	5.75%	6.01%	5.60%	5.53%	4.73%	6.08%	6.62%	7.62%	8.62%	9.62%	10.62%	*See tab "Historical Analysis" for assumptions
Change in NWC as % of Revenue	3.20%	-3.07%	5.61%	-2.13%	0.66%	1.65%	0.99%	0.99%	0.99%	0.99%	0.99%	*See tab "Historical Analysis" for assumptions
Effective Tax Rate	9.12%	-12.70%	73.49%	-4.85%	11.27%	6.69%	21.00%	21.00%	21.00%	21.00%	21.00%	*See tab "Historical Analysis" for assumptions

Bull Case	FY2016A	FY2017A	FY2018A	FY2019A	FY2020A	FY2021A	FY2022E	FY2023E	FY2024E	FY2025E	FY2026E
Revenue Growth		-3.1%	32.17%	8.18%	-1.00%	18.29%	-1.47%	3.42%	3.44%	3.45%	3.47%
COGS as a % of Revenue	43.60%	43.10%	42.91%	39.75%	43.87%	42.66%	44.65%	44.65%	44.65%	44.65%	44.65%
OpEx as a % of Revenue	30.71%	30.59%	31.41%	31.20%	31.67%	30.65%	34.04%	34.04%	34.04%	34.04%	34.04%
D&A as a % of Revenue	8.41%	7.76%	11.61%	12.32%	11.86%	10.54%	9.42%	9.42%	9.42%	9.42%	9.42%
CAPEX as a % of Revenue	5.75%	6.01%	5.60%	5.53%	4.73%	6.08%	6.42%	7.42%	8.42%	9.42%	10.42%
Change in NWC as % of Revenue	3.20%	-3.07%	5.61%	-2.13%	0.66%	1.65%	1.49%	1.49%	1.49%	1.49%	1.49%
Effective Tax Rate	9.12%	-12.70%	73.49%	-4.85%	11.27%	6.69%	19.00%	19.00%	19.00%	19.00%	19.00%

[Assumption 9](#)
[Assumption 10](#)
[Assumption 11](#)
[Assumption 12](#)
[Assumption 13](#)
[Assumption 14](#)
[Assumption 15](#)

Bear Case	FY2016A	FY2017A	FY2018A	FY2019A	FY2020A	FY2021A	FY2022E	FY2023E	FY2024E	FY2025E	FY2026E
Revenue Growth		-3.1%	32.17%	8.18%	-1.00%	18.29%	-1.97%	2.92%	2.94%	2.95%	2.97%
COGS as a % of Revenue	43.60%	43.10%	42.91%	39.75%	43.87%	42.66%	48.65%	48.65%	48.65%	48.65%	48.65%
OpEx as a % of Revenue	30.71%	30.59%	31.41%	31.20%	31.67%	30.65%	37.04%	37.04%	37.04%	37.04%	37.04%
D&A as a % of Revenue	8.41%	7.76%	11.61%	12.32%	11.86%	10.54%	11.42%	11.42%	11.42%	11.42%	11.42%
CAPEX as a % of Revenue	5.75%	6.01%	5.60%	5.53%	4.73%	6.08%	8.62%	9.62%	10.62%	11.62%	12.62%
Change in NWC as % of Revenue	3.20%	-3.07%	5.61%	-2.13%	0.66%	1.65%	0.49%	0.49%	0.49%	0.49%	0.49%
Effective Tax Rate	9.12%	-12.70%	73.49%	-4.85%	11.27%	6.69%	22.00%	22.00%	22.00%	22.00%	22.00%

[Assumption 16](#)
[Assumption 17](#)
[Assumption 18](#)
[Assumption 19](#)
[Assumption 20](#)
[Assumption 21](#)
[Assumption 22](#)

Analysis	FY2016A	FY2017A	FY2018A	FY2019A	FY2020A	FY2021A
<i>(millions of dollars)</i>						
<b>From Income Statement</b>						
Revenue	12,483	12,093	15,983	17,290	17,117	20,248
Revenue Annual Growth Rate		-3.12%	32.17%	8.18%	-1.00%	18.29%
COGS	5,442	5,212	6,859	6,872	7,510	8,638
COGS as a % of Revenue	43.60%	43.10%	42.91%	39.75%	43.87%	42.66%
COGS Annual Growth Rate		-4.23%	31.60%	0.19%	9.28%	15.02%
OpEx	3,833	3,699	5,020	5,394	5,421	6,206
OpEx as a % of Revenue	30.71%	30.59%	31.41%	31.20%	31.67%	30.65%
OpEx Annual Growth Rate		-0.38%	2.68%	-0.67%	1.52%	-3.22%
D&A	1,050	939	1,855	2,130	2,030	2,134
D&A as a % of Revenue	8.41%	7.76%	11.61%	12.32%	11.86%	10.54%
D&A as a % of Net PPE	26.92%	20.25%	34.51%	37.64%	32.01%	31.20%
D&A Annual Growth Rate		-10.57%	97.55%	14.82%	-4.69%	5.12%
Effective Tax Rate	9.12%	-12.70%	73.49%	-4.85%	11.27%	6.69%
<b>From Balance Sheet</b>						
Net PPE	3,901	4,638	5,375	5,659	6,341	6,839
Net PPE as a % of Revenue	31.25%	38.35%	33.63%	32.73%	37.05%	33.78%
Net PPE Annual Growth Rate		18.89%	15.89%	5.28%	12.05%	7.85%
<b>From Cash Flow Statement</b>						
Change in NWC	399	-371	897	-369	113	334
Change in NWC as % of Revenue	3.20%	-3.07%	5.61%	-2.13%	0.66%	1.65%
Change in NWC Annual Growth Rate		-192.98%	-341.78%	-141.14%	-130.62%	195.58%
CAPEX	718	727	895	957	810	1,231
CAPEX as a % of Revenue	5.75%	6.01%	5.60%	5.53%	4.73%	6.08%
CAPEX as a % of Net PPE	18.41%	15.67%	16.65%	16.91%	12.77%	18.00%
CAPEX Annual Growth Rate		1.25%	23.11%	6.93%	-15.36%	51.98%

Average	Standard Deviation	Correl. with Revenue
		100.00%
10.90%	14.60%	100.00%
42.65%	1.49%	98.22%
10.37%	14.06%	89.08%
31.04%	0.45%	99.73%
-0.02%	2.26%	16.95%
10.42%	1.91%	93.76%
30.42%	6.13%	87.72%
20.45%	44.17%	88.22%
13.84%	30.63%	12.98%
34.46%	2.69%	93.93%
11.99%	5.59%	-8.24%
0.99%	3.26%	16.18%
-122.19%	196.62%	-10.25%
5.62%	0.49%	90.12%
16.40%	2.03%	78.80%
13.58%	25.49%	68.65%

Revenue Build	FY2016A	FY2017A	FY2018A	FY2019A	FY2020A	FY2021A	FY2022E	FY2023E	FY2024E	FY2025E	FY2026E	
(millions of dollars)												
Medical	8,654	8,105	8,616	9,064	8,680	9,479	8,488	8,638	8,792	8,948	9,107	
Annual Growth Rate		-6.34%	6.30%	5.20%	-4.24%	9.21%	-10.46%	1.78%	1.78%	1.78%	1.78%	<a href="#">Assumption 23</a>
% of Total Revenues		67.02%	53.91%	52.42%	50.71%	46.81%	42.65%	42.07%	41.50%	40.93%	40.36%	
Life Sciences	3,829	3,988	4,330	4,300	4,675	6,530	6,993	7,286	7,591	7,909	8,240	
Annual Growth Rate		4.15%	8.58%	-0.69%	8.72%	39.68%	7.09%	4.19%	4.19%	4.19%	4.19%	<a href="#">Assumption 24</a>
% of Total Revenues		32.98%	27.09%	24.87%	27.31%	32.25%	35.14%	35.49%	35.83%	36.17%	36.51%	
Interventional	0	0	3,037	3,926	3,762	4,239	4,419	4,607	4,803	5,007	5,220	
Annual Growth Rate		n/a	n/a	29.27%	-4.18%	12.68%	4.25%	4.25%	4.25%	4.25%	4.25%	<a href="#">Assumption 25</a>
% of Total Revenues		n/a	19.00%	22.71%	21.98%	20.94%	22.21%	22.44%	22.67%	22.90%	23.13%	
<b>Total Revenue</b>	<b>12,483</b>	<b>12,093</b>	<b>15,983</b>	<b>17,290</b>	<b>17,117</b>	<b>20,248</b>	<b>19,900</b>	<b>20,531</b>	<b>21,186</b>	<b>21,864</b>	<b>22,568</b>	
Annual Growth Rate		-3.12%	32.17%	8.18%	-1.00%	18.29%	-1.72%	3.17%	3.19%	3.20%	3.22%	<a href="#">Assumption 1</a>

Analysis	FY2016A	FY2017A	FY2018A	FY2019A	FY2020A	FY2021A
(millions of dollars)						
Medical	8,654	8,105	8,616	9,064	8,680	9,479
Annual Growth Rate		-6.34%	6.30%	5.20%	-4.24%	9.21%
% of Total Revenues		67.02%	53.91%	52.42%	50.71%	46.81%
Life Sciences	3,829	3,988	4,330	4,300	4,675	6,530
Annual Growth Rate		4.15%	8.58%	-0.69%	8.72%	39.68%
% of Total Revenues		32.98%	27.09%	24.87%	27.31%	32.25%
Interventional	0	0	3,037	3,926	3,762	4,239
Annual Growth Rate				29.27%	-4.18%	12.68%
% of Total Revenues			19.00%	22.71%	21.98%	20.94%
	12,483	12,093	15,983	17,290	17,117	20,248
Annual Growth Rate		-3.12%	32.17%	8.18%	-1.00%	18.29%

Average	Standard Deviation
2.03%	6.88%
12.09%	15.90%
12.59%	16.72%
10.90%	14.60%

Scenarios & Other Inputs		
Case Number	1	
Selected Case	Base	
Risk Free Rate	2.47%	Assumption 29
Beta	0.67	
Cost of Equity	6.13%	
Cost of Debt	2.41%	
Terminal Growth Rate	2.00%	
Tax Rate	21.00%	
WACC	5.29%	

Case Guide		
1	Base	
2	Bull	
3	Bear	

DCF Projections											
FY Ending September							1	2	3	4	5
FCF	FY2016A	FY2017A	FY2018A	FY2019A	FY2020A	FY2021A	FY2022E	FY2023E	FY2024E	FY2025E	FY2026E
(millions of dollars)											
Revenue	12,483	12,093	15,983	17,290	17,117	20,248	19,900	20,531	21,186	21,864	22,568
COGS	5,442	5,212	6,859	6,872	7,510	8,638	9,084	9,372	9,671	9,981	10,302
OpEx	3,833	3,699	5,020	5,394	5,421	6,206	6,972	7,193	7,423	7,661	7,907
EBIT	3,208	3,182	4,104	5,024	4,186	5,404	3,844	3,966	4,092	4,223	4,359
Taxes	293	-404	3,016	-244	472	362	807	833	859	887	915
NOPAT	2,915	3,586	1,088	5,268	3,714	5,042	3,036	3,133	3,233	3,336	3,444
+ D&A	1,050	939	1,855	2,130	2,030	2,134	2,073	2,139	2,207	2,278	2,351
- Change in NWC	399	-371	897	-369	113	334	196	202	209	216	223
- CAPEX	718	727	895	957	810	1,231	1,317	1,564	1,826	2,103	2,396
FCF	2,848	4,169	1,151	6,810	4,821	5,611	3,596	3,505	3,405	3,295	3,176
Discount Factor							0.9498	0.9020	0.8567	0.8137	0.7728
Discounted FCF							3,415	3,162	2,917	2,681	2,454

Terminal Value Calculation

Terminal Value	
Terminal Year	FY2027
Terminal Cash Flow	3,239
Terminal Growth Rate	2.00%
Discount Rate	5.29%
Terminal Value	98,445
PV of Terminal Value	76,077

Value per Share	
Enterprise Value	90,706
Debt	18,520
Cash	2,404
FCFE	74,590
No. of Shares	285
Value per Share	261.93
Value per Share Adjusted to Jan 24, 2022:	
Enterprise Value, Jan 24, 2022	92,204
FCFE, Jan 24, 2022	76,088
No. of Shares	284.8
Value per Share, Jan 24, 2022	267.19
Actual Value per Share on Jan 24, 2022	252.72
Over (Under) Valued	-14.47

Implied Equity Value, and Share Price

Valuation by Multiples - PE LTM	
Peer Group's PE Ratio LTM	45.6x
LTM Net Income	2,002
Equity Value	91,376
Number of Shares Outstanding	285
Implied Share Price	320.88
Actual Share Price Jan 24th, 2022	252.70
Over (under) valued	-68.18

Valuation by Multiples - EV/EBIT	
Peer Group's EV/EBIT	34.41
EBX EBIT	2815
Enterprise Value	96860
Number of Shares Outstanding	285
Implied Share Price	340.13
Actual Share Price Jan 24th, 2022	252.70
Over (under) valued	-87.43

Valuation by Multiples - Conclusion	
Concluded Fair Value	330.50
Actual Share Price Jan 24th, 2022	252.70
Over (under) valued	-77.80

Share Price Sensitivity Analysis

		WACC						
		3.79%	4.29%	4.79%	5.29%	5.79%	6.29%	6.79%
Terminal Growth	0.50%	283.72	239.79	206.09	179.41	157.77	139.86	124.80
	1.00%	336.68	278.09	234.95	201.85	175.66	154.40	136.82
	1.50%	412.76	330.12	272.58	230.21	197.71	171.98	151.11
	2.00%	531.34	404.87	323.70	267.19	225.58	193.65	168.38
	2.50%	741.83	521.37	397.14	317.42	261.92	221.04	189.68
	3.00%	1218.67	728.16	511.61	389.59	311.28	256.76	216.60
	3.50%	3338.41	1196.64	714.79	502.07	382.20	305.27	251.71

		Cost of Equity						
		4.63%	5.13%	5.63%	6.13%	6.63%	7.13%	7.63%
Cost of Debt	0.91%	511.76	412.26	342.78	291.52	252.13	220.92	195.58
	1.41%	489.00	396.76	331.55	283.00	245.46	215.55	191.16
	1.91%	468.02	382.26	320.94	274.90	239.07	210.38	186.89
	2.41%	448.61	368.69	310.91	267.19	232.95	205.41	182.78
	2.91%	430.61	355.94	301.41	259.84	227.09	200.63	178.81
	3.41%	413.87	343.95	292.40	252.82	221.47	196.03	174.97
	3.91%	398.26	332.64	283.84	246.11	216.08	191.59	171.26

		Terminal Growth						
		0.50%	1.00%	1.50%	2.00%	2.50%	3.00%	3.50%
Tax Rate	36%	182.90	206.13	235.60	274.24	327.08	403.75	525.04
	31%	181.72	204.69	233.78	271.85	323.81	398.93	517.17
	26%	180.56	203.26	231.99	269.50	320.59	394.21	509.52
	21%	179.41	201.85	230.21	267.19	317.42	389.59	502.07
	16%	178.27	200.46	228.46	264.91	314.31	385.06	494.81
	11%	177.14	199.08	226.73	262.66	311.25	380.63	487.75
	6%	176.03	197.71	225.02	260.44	308.25	376.29	480.87

Comps Tables - FactSet RBICS Sub-Sector - General Medical Devices [Assumption 28](#)

## Selected Financials

		Market Data (\$)				Financial (\$)				Valuation (x)		
Company		Fiscal				Shares Out	Shares Out			EV/	EV/	
Name	Ticker	Period	Price	Mkt Cap (M)	EV (M)	(M)	Diluted (M)	Sales (M)	EBIT (M)	EBITDA (M)	EBIT	EBITDA
Becton, Dickinson	BDX-US	12/31/2021	267.60	76,204.7	91,575.7	284.8	286.7	19,927.0	2,815.0	5,090.0	32.53x	17.99x
Edwards Lifesciences	EW-US	12/2021	111.55	69,518.8	68,740.8	623.2	631.2	5,232.5	1,610.4	1,773.7	42.69x	38.76x
Boston Scientific	BSX-US	12/2021	44.32	63,232.4	70,644.4	1,426.7	1,433.8	11,888.0	1,922.0	3,015.0	36.76x	23.43x
Stryker Corp	SYK-US	12/2021	265.79	100,347.6	110,229.6	377.5	382.3	17,108.0	3,661.0	4,651.0	30.11x	23.70x
Intuitive Surgical	ISRG-US	12/2021	283.28	101,752.7	97,686.1	359.2	365.8	5,710.1	1,821.0	2,138.0	53.64x	45.69x
Baxter Intl	BAX-US	12/2021	79.05	39,706.3	55,104.3	502.3	508.0	12,784.0	2,083.0	2,973.0	26.45x	18.53x
Danaher	DHR-US	12/2021	289.27	206,930.0	230,894.0	715.4	736.8	29,453.0	8,050.0	10,218.0	28.68x	22.60x
Abbott Laboratories	ABT-US	12/2021	121.76	215,306.6	224,530.6	1,768.3	1,789.0	43,075.0	9,200.0	12,738.0	24.41x	17.63x
Average											34.41x	26.04x
Median											31.32x	23.01x

## Valuation

		P/E (x)				EV/ (x)				Financial (\$)			
Company		Fiscal	FY1										
Name	Ticker	Period	Date	EV (M)	Actual	FY1	FY2	Sales	EBIT	EBITDA	Sales (M)	EBIT (M)	EBITDA (M)
Becton, Dickinson	BDX-US	12/31/2021	09/2022	91,575.7	46.25x	20.71x	19.18x	4.60x	32.53x	17.99x	19,927.0	2,815.0	5,090.0
Edwards Lifesciences	EW-US	12/2021	12/2022	68,740.8	46.84x	43.83x	38.80x	13.14x	42.69x	38.76x	5,232.5	1,610.4	1,773.7
Boston Scientific	BSX-US	12/2021	12/2022	70,644.4	64.51x	25.02x	22.08x	5.94x	36.76x	23.43x	11,888.0	1,922.0	3,015.0
Stryker Corp	SYK-US	12/2021	12/2022	110,229.6	50.96x	27.14x	24.25x	6.44x	30.11x	23.70x	17,108.0	3,661.0	4,651.0
Intuitive Surgical	ISRG-US	12/2021	12/2022	97,686.1	60.79x	56.47x	47.83x	17.11x	53.64x	45.69x	5,710.1	1,821.0	2,138.0
Baxter Intl	BAX-US	12/2021	12/2022	55,104.3	31.27x	18.39x	16.10x	4.31x	26.45x	18.53x	12,784.0	2,083.0	2,973.0
Danaher	DHR-US	12/2021	12/2022	230,894.0	33.58x	27.71x	26.16x	7.84x	28.68x	22.60x	29,453.0	8,050.0	10,218.0
Abbott Laboratories	ABT-US	12/2021	12/2022	224,530.6	30.93x	25.11x	23.74x	5.21x	24.41x	17.63x	43,075.0	9,200.0	12,738.0
Average					45.64x	30.55x	27.27x	8.07x	34.41x	26.04x			
Median					46.55x	26.13x	23.99x	6.19x	31.32x	23.01x			

Becton, Dickinson and Company  
 BDJ 075887109 2087807 NYSE Common stock

Instrument ID	Description	Balance Sheet Amt Out (USD)	Current Amt Out (USD)	Coupon Rate	Coupon Type	Issue Date	Maturity Date	Issue Curr	Seniority	Price	YTW	OAS (LIBOR)
<b>ST Debt</b>		<b>1,064.0</b>	<b>1,064.0</b>									
-	Current Portion Of LTD	1,064.0	1,064.0	-	-	-	-	USD	Other	-	-	-
<b>Revolving Credit</b>		<b>0.0</b>	<b>0.0</b>									
FDS1OTGB4	Senior Unsec. Revolving Credit Facility	0.0	0.0	-	Variable	09/2021	09/2026	USD	SNR Unsec	-	-	-
<b>Notes/Bonds</b>		<b>17,509.9</b>	<b>17,509.9</b>									
075887BU2	Becton Dickinson & Co - FRN	500.0	500.0	-	Variable	06/2017	06/2022	USD	SNR Unsec	100.08	1.27	40.10
075887BN8	Becton Dickinson & Co - 500M EUR	568.6	568.6	1.000%	Fixed	12/2016	12/2022	EUR	SNR Unsec	100.70	0.06	37.33
075887CH0	Becton Dickinson & Co - MTN - 300M EUR	341.2	341.2	1.401%	Fixed	05/2018	05/2023	EUR	SNR Unsec	101.33	0.19	31.33
075887CM9	Becton Dickinson & Co - 400M EUR	454.9	454.9	-	Fixed	08/2021	08/2023	EUR	SNR Unsec	99.43	0.41	37.84
07589LAB3	Becton Dickinson Euro Finance SARL - 800M EUR	909.8	909.8	0.632%	Fixed	06/2019	06/2023	EUR	SNR Unsec	100.58	0.12	19.93
075887BL2	Becton Dickinson & Co	143.6	143.6	3.875%	Fixed	04/2015	05/2024	USD	SNR Unsec	101.59	3.01	80.92
075887BF5	Becton Dickinson & Co	875.0	875.0	3.734%	Fixed	12/2014	12/2024	USD	SNR Unsec	102.03	2.88	59.02
075887BV0	Becton Dickinson & Co	997.7	997.7	3.363%	Fixed	06/2017	06/2024	USD	SNR Unsec	101.40	2.65	42.34
075887CG2	Becton Dickinson & Co - 250M GBP	338.6	338.6	3.020%	Fixed	05/2018	05/2025	GBP	SNR Unsec	101.66	2.43	57.91
075887CN7	Becton Dickinson & Co - 500M EUR	568.6	568.6	0.034%	Fixed	08/2021	08/2025	EUR	SNR Unsec	96.85	0.98	43.44
067383AA7	CR Bard Inc	12.8	12.8	6.700%	Fixed	12/1996	12/2026	USD	SNR Unsec	107.32	4.93	269.44
075887CE7	Becton Dickinson & Co	134.0	134.0	6.700%	Fixed	04/2018	12/2026	USD	SNR Unsec	114.29	3.39	114.65
075887BP3	Becton Dickinson & Co - 500M EUR	568.6	568.6	1.900%	Fixed	12/2016	12/2026	EUR	SNR Unsec	102.97	1.21	52.51
07589LAC1	Becton Dickinson Euro Finance SARL - 600M EUR	682.3	682.3	1.208%	Fixed	06/2019	06/2026	EUR	SNR Unsec	100.02	1.20	53.93
075887AN9	Becton Dickinson & Co	168.0	168.0	7.000%	Fixed	07/1997	08/2027	USD	SNR Unsec	117.89	3.33	110.02
075887BW8	Becton Dickinson & Co	1,725.0	1,725.0	3.700%	Fixed	06/2017	06/2027	USD	SNR Unsec	102.53	3.14	88.90
075887AQ2	Becton Dickinson & Co	167.1	167.1	6.700%	Fixed	08/1998	08/2028	USD	SNR Unsec	117.20	3.65	141.33
L076BMAA2	Becton Dickinson Euro Finance SARL - 900M EUR	1,023.5	1,023.5	0.334%	Fixed	08/2021	08/2028	EUR	SNR Unsec	92.48	1.57	76.54
075887CJ6	Becton Dickinson & Co	750.0	750.0	2.823%	Fixed	05/2020	05/2030	USD	SNR Unsec	95.71	3.43	117.53
075887CL1	Becton Dickinson & Co	1,000.0	1,000.0	1.957%	Fixed	02/2021	02/2031	USD	SNR Unsec	89.00	3.40	114.19
07589LAD9	Becton Dickinson & Co - 600M EUR	682.3	682.3	1.213%	Fixed	02/2021	02/2036	EUR	SNR Unsec	88.10	2.20	108.15
075887AV1	Becton Dickinson & Co	250.0	250.0	6.000%	Fixed	05/2009	05/2039	USD	SNR Unsec	119.82	4.35	202.37
075887AX7	Becton Dickinson & Co	125.0	125.0	5.000%	Fixed	11/2010	11/2040	USD	SNR Unsec	108.32	4.34	201.12
L076BMAA4	Becton Dickinson Euro Finance SARL - 900M EUR	1,023.5	1,023.5	1.336%	Fixed	08/2021	08/2041	EUR	SNR Unsec	82.40	2.48	136.79
075887BM0	Becton Dickinson & Co	224.9	224.9	4.875%	Fixed	04/2015	05/2044	USD	SNR Unsec	108.04	4.30	196.74
075887BG3	Becton Dickinson & Co	1,025.0	1,025.0	4.685%	Fixed	12/2014	12/2044	USD	SNR Unsec	107.85	4.14	181.10
075887BX6	Becton Dickinson & Co	1,500.0	1,500.0	4.669%	Fixed	06/2017	06/2047	USD	SNR Unsec	108.67	4.11	179.48
075887CK3	Becton Dickinson & Co	750.0	750.0	3.794%	Fixed	05/2020	05/2050	USD	SNR Unsec	95.38	4.07	178.11
<b>Other</b>		<b>-85.9</b>	<b>-85.9</b>									
-	Unamortized Issuance Costs - Senior Unsecured Notes	-85.9	-85.9	-	-	-	-	USD	Other	-	-	-
	LT Debt Total	17,424.0										
	Current Portion of LTD	-1,064.0										
	Net LT Debt Total	16,360.0										
	ST Debt Total	1,064.0										
	Total Debt	17,424.0	17,424.0									

Data as of 18 Mar '22 Amount Outstanding in millions of USD

Source: FactSet DCS and FactSet Fixed Income

\* The current total debt outstanding value is not considered a reconciled amount. Activity is determined on a transactional basis and there can be events that may affect amounts that are not disclosed until the next filing date.



Becton, Dickinson and Company

BDX 075887109 2087807 NYSE Common stock

	Book Value	Price(as % of par)	Market Value	MV percentage of Total Debt	YTW(%)	
Instrument ID						
<b>ST Debt</b>	<b>1,064.0</b>	<b>-</b>	1,064.0	5.75%	0	0
<b>Notes/Bonds</b>						
075887BU2	500.0	100.08	500.4	2.70%	1.27	0.034314138
075887BN8	568.6	100.70	572.5802	3.09%	0.06	0.001854982
075887CH0	341.2	101.33	345.73796	1.87%	0.19	0.003546931
075887CM9	454.9	99.43	452.30707	2.44%	0.41	0.010013117
07589LAB3	909.8	100.58	915.07684	4.94%	0.12	0.005929129
075887BL2	143.6	101.59	145.88324	0.79%	3.01	0.023709586
075887BF5	875.0	102.03	892.7625	4.82%	2.88	0.138829096
075887BV0	997.7	101.40	1011.6678	5.46%	2.65	0.144755765
075887CG2	338.6	101.66	344.22076	1.86%	2.43	0.045164312
075887CN7	568.6	96.85	550.6891	2.97%	0.98	0.02913967
067383AA7	12.8	107.32	13.73696	0.07%	4.93	0.003656702
075887CE7	134.0	114.29	153.1486	0.83%	3.39	0.028032691
075887BP3	568.6	102.97	585.48742	3.16%	1.21	0.038252076
07589LAC1	682.3	100.02	682.43646	3.68%	1.20	0.044217638
075887AN9	168.0	117.89	198.0552	1.07%	3.33	0.035610867
075887BW8	1,725.0	102.53	1768.6425	9.55%	3.14	0.299862234
075887AQ2	167.1	117.20	195.8412	1.06%	3.65	0.038596595
L076BMAB2	1,023.5	92.48	946.5328	5.11%	1.57	0.080239347
075887CJ6	750.0	95.71	717.825	3.88%	3.43	0.132942783
075887CL1	1,000.0	89.00	890	4.81%	3.40	0.163388314
07589LAD9	682.3	88.10	601.1063	3.25%	2.20	0.071404573
075887AV1	250.0	119.82	299.55	1.62%	4.35	0.07035754
075887AX7	125.0	108.32	135.4	0.73%	4.34	0.031729298
L076BMAA4	1,023.5	82.40	843.364	4.55%	2.48	0.112932465
075887BM0	224.9	108.04	242.98196	1.31%	4.30	0.056414995
075887BG3	1,025.0	107.85	1105.4625	5.97%	4.14	0.247113473
075887BX6	1,500.0	108.67	1630.05	8.80%	4.11	0.361738569
075887CK3	750.0	95.38	715.35	3.86%	4.07	0.157204531
<b>Other</b>	<b>-85.9</b>					
-	-85.9					
<b>LT Debt Total</b>			17456.29637		1	
<b>ST Debt Total</b>			1,064.0		<b>Cost of debt</b>	<b>2.410951417</b>
<b>Total Debt</b>			18,520.29637			

Date	Open	High	Low	Close	Adj Close	Volume	Return for Beckton dickson
2017-04-01	184	187.299997	175.660004	186.970001	174.865485	3123040	1.21%
2017-05-01	186.380005	190.710007	177.699999	189.229996	177.080383	5904400	3.11%
2017-06-01	188.369995	196.589996	188.300003	195.110001	182.582855	31272500	3.62%
2017-07-01	195.789993	206.630005	194.220003	198.120005	189.180755	22497400	-0.97%
2017-08-01	201.699997	202.899994	200.899996	199.440002	187.347534	25729600	-1.75%
2017-09-01	199.440002	204.860001	191.520000	195.949997	184.082168	25985100	6.88%
2017-10-01	196.930004	214.770001	191.050003	206.669996	196.786785	25966300	9.38%
2017-11-01	207.529999	228.800003	203.990005	228.210007	215.143145	26588300	-6.20%
2017-12-01	226.770004	229.890002	214.990007	214.050007	203.838007	29028300	13.88%
2018-01-01	215.089996	246.389999	215.089996	243.240002	229.818713	31713840	-8.61%
2018-02-01	241.080002	243.509995	208.910004	222.020004	210.040529	29950400	-2.40%
2018-03-01	221.600006	227.800003	216.300005	222.020004	210.040529	29950400	7.17%
2018-04-01	215.990005	236.130005	210.210007	231.869995	220.117294	23730300	-4.41%
2018-05-01	230.770004	234.300006	218.600006	221.589996	210.318307	28300000	8.11%
2018-06-01	233.320007	242.639999	233.030003	239.550008	227.471496	24748000	4.85%
2018-07-01	237.449997	252.740005	235.330002	250.369995	238.451706	17394900	4.59%
2018-08-01	250.050003	262.670013	239.800003	261.869995	249.404246	18975800	-0.31%
2018-09-01	262.140015	264.670001	251.210007	261	248.576548	18236800	-11.41%
2018-10-01	262	265.869995	225.339996	230.5	220.16884	26193800	9.60%
2018-11-01	230.580002	251.520007	225	252.75	241.421373	26747700	-10.88%
2018-12-01	253.940002	256.040009	208.619995	253.320007	251.220871	24604600	11.07%
2019-01-01	221.970001	249.869995	221.970001	249.460007	239.04387	24353700	-0.27%
2019-02-01	249.770004	254	237.75	248.789999	238.289441	19094300	0.28%
2019-03-01	250.529999	257.160004	238.210007	249.729996	239.300583	22842300	-3.30%
2019-04-01	250.890005	253.830002	221.509995	240.740005	231.402882	30777900	-3.03%
2019-05-01	240.899993	246.729996	221.470003	231.440002	224.389595	33310300	7.93%
2019-06-01	233.970001	252.410004	231.25	251.009995	242.235748	25466000	0.64%
2019-07-01	253.160004	258.050006	249.589996	251.800003	243.779262	17894000	0.84%
2019-08-01	252.899994	257.770011	229	251.817998	244.482599	23576500	-0.38%
2019-09-01	251.160004	264.739999	246.910004	252.960007	243.933578	21646700	1.50%
2019-10-01	254.220001	259.149994	244.089996	256	247.652676	23088000	0.98%
2019-11-01	257.700012	261.080002	240.610003	258.5	250.020706	26774000	5.21%
2019-12-01	258.099996	271.480011	251.580002	271.070001	261.048889	23036900	1.49%
2020-01-01	272.089996	281.050012	266.649994	275.179993	266.962485	26913700	-11.58%
2020-02-01	277.200011	286.720001	231.619995	277.820007	230.758216	48519900	-3.88%
2020-03-01	277.839996	251.070001	197.75	229.770004	222.968085	64814000	-10.27%
2020-04-01	211.710007	271.050012	220	251.320000	240.470000	40477000	-2.22%
2020-05-01	250.800003	248.420013	227.410004	246.929993	240.16022	51191400	-3.10%
2020-06-01	246.830005	250.320007	225.300003	239.770004	233.843631	45114000	17.97%
2020-07-01	239.099993	281.350006	238.759995	281.339996	274.740204	26899100	-13.71%
2020-08-01	282.970001	284.970001	232	242.770004	237.074982	32428100	-4.16%
2020-09-01	243.970001	246.679993	193.5	231.679993	227.211649	36171100	-0.31%
2020-10-01	234.410004	246.869995	227.820007	231.130005	226.472366	23414700	1.61%
2020-11-01	233.610001	247.830002	236.149994	234.839996	230.10759	33711200	6.55%
2020-12-01	236.139995	251.229996	234.610001	250.220001	245.177658	28737600	4.99%
2021-01-01	251	267.369995	246.75	261.790009	257.483889	25660300	-7.88%
2021-02-01	262.430012	265.010009	244.009995	241.149994	237.286129	27245500	0.82%
2021-03-01	242.710007	240.639999	236.029999	243.149994	239.076096	28799600	2.67%
2021-04-01	243.550003	262.010001	240.570007	248.809998	245.469113	26180500	-2.78%
2021-05-01	240.710007	251.759995	238.189997	241.889999	238.642059	32361000	0.54%
2021-06-01	241.130005	247.660004	237.339996	243.190002	239.924622	32513700	5.53%
2021-07-01	243.099995	256.820007	242.090002	255.75	251.138192	21619900	-1.58%
2021-08-01	256.399995	257.929993	237.339993	251.699997	249.138485	31277600	-2.34%
2021-09-01	251.979996	264	245.789993	245.820007	243.362473	80418500	-2.22%
2021-10-01	246.429993	248.479996	236.130005	239.589996	237.962785	30450500	-1.02%
2021-11-01	239.529993	252.410004	236	237.139999	235.527651	32500000	6.09%
2021-12-01	237.610004	259.399994	236.619995	251.479996	249.709943	28718500	1.42%
2022-01-01	250.229996	268.549998	246.919996	254.139999	253.330601	29132900	6.74%
2022-02-01	254.360001	280.619995	250.929993	277.279999	270.388832	27708300	-3.41%
2022-03-01	271	276.489999	254.169998	262.040009	261.180145	19861800	0.33%
2022-03-18	261.210004	262.839996	257.729999	262.040009	261.240009	2612475	

	Open	High	Low	Close*	Adj Close**	Volume
01-Apr-17	2362.31	2398.15	2398.15	2338.95		65,265,670,000
01-May-17	2388.50	2418.71	2352.72	2411.80	2411.80	79,607,170,000
01-Jun-17	2415.65	2453.82	2405.70	2423.41	2423.41	81,002,490,000
01-Jul-17	2433.39	2484.04	2407.70	2479.30	2479.30	61,348,400,000
01-Aug-17	2477.30	2490.87	2417.35	2471.65	2471.65	70,616,030,000
01-Sep-17	2474.42	2519.44	2446.55	2519.36	2519.36	66,337,980,000
01-Oct-17	2521.20	2582.98	2520.40	2573.26	2573.26	70,871,170,000
01-Nov-17	2583.21	2657.74	2557.45	2647.58	2647.58	73,173,260,000
01-Dec-17	2685.39	2694.87	2605.52	2673.61	2673.61	65,251,190,000
01-Jan-18	2683.73	2677.87	2682.36	2621.81	2621.81	78,860,120,000
01-Feb-18	2816.45	2835.96	2532.69	2713.83	2713.83	79,579,410,000
01-Mar-18	2715.12	2801.89	2648.05	2783.89	2783.89	70,500,800,000
01-Apr-18	2633.45	2717.49	2553.80	2648.05	2648.05	69,648,950,000
01-May-18	2642.96	2742.24	2594.62	2705.27	2705.27	75,617,280,000
01-Jun-18	2718.70	2795.47	2691.99	2718.37	2718.37	77,438,710,000
01-Jul-18	2704.95	2848.03	2698.95	2816.29	2816.29	64,542,170,000
01-Aug-18	2821.17	2916.50	2796.34	2901.52	2901.52	69,238,220,000
01-Sep-18	2896.96	2940.91	2864.12	2931.08	2931.08	62,492,080,000
01-Oct-18	2926.29	2939.86	2603.54	2711.74	2711.74	91,327,930,000
01-Nov-18	2717.58	2815.15	2681.09	2780.17	2780.17	80,080,110,000
01-Dec-18	2790.50	2800.18	2346.58	2568.85	2568.85	81,522,570,000
01-Jan-19	2476.96	2708.95	2443.96	2704.10	2704.10	80,401,630,000
01-Feb-19	2702.32	2813.49	2683.82	2784.49	2784.49	70,182,430,000
01-Mar-19	2798.22	2860.31	2722.27	2834.40	2834.40	78,596,280,000
01-Apr-19	2848.63	2949.52	2848.63	2945.83	2945.83	69,604,840,000
01-May-19	2952.33	2954.13	2750.52	2750.06	2750.06	78,860,120,000
01-Jun-19	2751.53	2964.15	2728.81	2941.76	2941.76	70,904,280,000
01-Jul-19	2971.41	3017.98	2952.22	2980.58	2980.58	70,349,470,000
01-Aug-19	2980.32	3013.09	2822.12	2958.46	2958.46	78,599,460,000
01-Sep-19	2909.01	3021.99	2891.85	2976.74	2976.74	73,992,330,000
01-Oct-19	2980.49	3050.10	2853.94	3037.56	3037.56	77,544,550,000
01-Nov-19	3050.72	3154.26	3050.72	3140.98	3140.98	72,178,930,000
01-Dec-19	3143.85	3247.93	3070.33	3230.78	3230.78	72,654,000,000
01-Jan-20	3244.67	3337.77	3214.64	3229.52	3229.52	77,654,030,000
01-Feb-20	3235.46	3393.52	2855.84	2954.22	2954.22	84,292,270,000
01-Mar-20	2974.28	3136.72	2191.86	2941.76	2941.76	101,801,100,000
01-Apr-20	2498.08	2954.86	2447.49	2912.43	2912.43	121,161,450,000
01-May-20	2680.09	3068.67	2766.64	3044.31	3044.31	106,799,100,000
01-Jun-20	3028.78	3233.13	2965.66	3100.29	3100.29	121,044,000,000
01-Jul-20	3105.52	3279.99	3101.17	3271.12	3271.12	97,197,020,000
01-Aug-20	3288.26	3514.77	3264.53	3500.31	3500.31	84,402,300,000
01-Sep-20	3507.44	3588.11	3309.45	3363.00	3363.00	91,084,120,000
01-Oct-20	3385.87	3549.85	3233.94	3269.96	3269.96	89,737,600,000
01-Nov-20	3206.20	3645.99	3279.74	3621.63	3621.63	100,977,880,000
01-Dec-20	3645.87	3780.20	3633.40	3756.07	3756.07	96,065,420,000
01-Jan-21	3764.61	3870.90	3662.71	3714.24	3714.24	105,548,790,000
01-Feb-21	3731.17	3950.43	3725.62	3811.15	3811.15	98,596,960,000
01-Mar-21	3842.51	3994.41	3723.34	3972.89	3972.89	120,863,560,000
01-Apr-21	3992.78	4218.78	3992.78	4181.17	4181.17	82,869,190,000
01-May-21	4192.98	4398.98	4192.98	4378.12	4378.12	86,205,280,000
01-Jun-21	4215.82	4324.83	4164.40	4297.50	4297.50	80,785,120,000
01-Jul-2021	4300.73	4299.73	4300.73	4395.26	4395.26	69,496,490,000
01-Aug-21	4306.87	4337.57	4306.87	4375.68	4375.68	70,500,800,000
01-Sep-21	4328.80	4458.85	4309.91	4397.42	4397.42	66,268,650,000
01-Oct-21	4431.18	4408.08	4278.84	4405.38	4405.38	61,874,770,000
01-Nov-21	4406.82	4460.82	4376.18	4447.18	4447.18	67,617,280,000
01-Dec-21	4602.82	4602.82	4391.12	4766.18	4766.18	69,604,840,000
01-Jan-22	4778.14	4778.14	4222.43	4715.18	4715.18	70,182,430,000
01-Feb-22	4519.57	4596.31	4144.65	4378.94	4378.94	71,173,790,000
01-Mar-22	4633.14	4600.46	4357.46	4412.12	4412.12	65,251,190,000
01-Apr-22	4407.34	4607.34	4357.46	4412.12	4412.12	78,860,120,000

Total Equity(in millions)	74621	weight of equitiy	80.1159%
Total Debt(in millions)	18520.29637	weight of debt	19.8841%
Cost of debt	2.4110%	DE Ratio	24.8191%
Cost of Equity	6.1305%	<b>WACC</b>	<b>5.29024%</b>
Tax rate	0.21 <a href="#">Assumption 6</a>		

### Competitive Comparison Data

Ticker	Company	Market Cap (M)	WACC %
BDX	Becton, Dickinson and Co	\$ 74,621.41	4.51
ISRG	Intuitive Surgical Inc	\$ 104,206.01	7.99
BAX	Baxter International Inc	\$ 39,741.47	4.43
RMD	ResMed Inc	\$ 38,235.87	2.50
WST	West Pharmaceutical Servic...	\$ 30,803.83	6.56
COO	The Cooper Companies Inc	\$ 20,771.24	6.29
HOLX	Hologic Inc	\$ 18,726.31	8.00
TFX	Teleflex Inc	\$ 16,401.22	7.85
LTS:0LNU	Varian Medical Systems Inc	\$ 16,272.82	0.00
RGEN	Repligen Corp	\$ 10,591.34	5.85

Becton, Dickinson and Company (BDX)

\$262.04

Becton, Dickinson and Company

BDX 075887109 2087807 NYSE Common stock

Source: FactSet Fundamentals

	SEP '16	SEP '17	SEP '18	SEP '19	SEP '20	SEP '21
	Restate					
<b>Sales</b>	<b>12,483</b>	<b>12,093</b>	<b>15,983</b>	<b>17,290</b>	<b>17,117</b>	<b>20,248</b>
<b>Cost of Goods Sold (COGS) incl. D&amp;A</b>	<b>6,492</b>	<b>6,151</b>	<b>8,714</b>	<b>9,002</b>	<b>9,540</b>	<b>10,772</b>
COGS excluding D&A	5,442	5,212	6,859	6,872	7,510	8,638
<b>Depreciation &amp; Amortization Expense</b>	<b>1,050</b>	<b>939</b>	<b>1,855</b>	<b>2,130</b>	<b>2,030</b>	<b>2,134</b>
Depreciation	452	406	600	633	646	731
Amortization of Intangibles	598	533	1,255	1,497	1,384	1,403
<b>Gross Income</b>	<b>5,991</b>	<b>5,942</b>	<b>7,269</b>	<b>8,288</b>	<b>7,577</b>	<b>9,476</b>
<b>SG&amp;A Expense</b>	<b>3,833</b>	<b>3,699</b>	<b>5,020</b>	<b>5,394</b>	<b>5,421</b>	<b>6,206</b>
Research & Development	828	774	1,004	1,062	1,096	1,339
Other SG&A	3,005	2,925	4,016	4,332	4,325	4,867
<b>EBIT (Operating Income)</b>	<b>2,158</b>	<b>2,243</b>	<b>2,249</b>	<b>2,894</b>	<b>2,156</b>	<b>3,270</b>
<b>Nonoperating Income - Net</b>	<b>54</b>	<b>103</b>	<b>400</b>	<b>-552</b>	<b>-309</b>	<b>229</b>
Nonoperating Interest Income	29	79	73	30	7	9
Other Income (Expense)	25	24	327	-582	-316	220
<b>Interest Expense</b>	<b>407</b>	<b>521</b>	<b>706</b>	<b>639</b>	<b>528</b>	<b>469</b>
Gross Interest Expense	437	553	748	683	571	513
Interest Capitalized	30	32	42	44	43	44
<b>Unusual Expense - Net</b>	<b>731</b>	<b>849</b>	<b>770</b>	<b>527</b>	<b>334</b>	<b>788</b>
<b>Impairments</b>						<b>49</b>
Other Intangibles	0	0	0	0	0	0
Property, Plant & Equipment						49
Exceptional Provisions	0	411				
Restructuring Expense	728	354	740	480	309	185
Legal Claim Expense						363
<b>Unrealized Valuation Gain/Loss</b>	<b>-3</b>	<b>-11</b>	<b>-14</b>	<b>-23</b>	<b>-17</b>	<b>-13</b>
Hedges/Derivatives	-3	-11	-14	-23	-17	-13
<b>Excp'l Chrgs - Others</b>		<b>73</b>	<b>16</b>	<b>24</b>	<b>8</b>	<b>178</b>
Restructuring of Debt		73	16	59	8	178
Early termination of Contracts costs (Income)						
Calamitous Events			0	-35	0	0
<b>Pretax Income</b>	<b>1,074</b>	<b>976</b>	<b>1,173</b>	<b>1,176</b>	<b>985</b>	<b>2,242</b>
<b>Income Taxes</b>	<b>98</b>	<b>-124</b>	<b>862</b>	<b>-57</b>	<b>111</b>	<b>150</b>
Income Taxes - Current Domestic	331	-250	737	276	-3	148
Income Taxes - Current Foreign	286	200	387	300	400	290
Income Taxes - Deferred Domestic	-441	-64	-201	-566	-185	-286
Income Taxes - Deferred Foreign	-78	-10	-61	-67	-101	-2
Other After Tax Adjustments	0	0	0	1	0	0
<b>Consolidated Net Income</b>	<b>976</b>	<b>1,100</b>	<b>311</b>	<b>1,234</b>	<b>874</b>	<b>2,092</b>
<b>Net Income</b>	<b>976</b>	<b>1,100</b>	<b>311</b>	<b>1,234</b>	<b>874</b>	<b>2,092</b>
Discontinued Operations	0	0	0	0	0	0
Preferred Dividends	0	70	152	152	107	90
<b>Net Income available to Common</b>	<b>976</b>	<b>1,030</b>	<b>159</b>	<b>1,082</b>	<b>767</b>	<b>2,002</b>
<b>Per Share</b>						
<b>EPS (recurring)</b>	<b>6.84</b>	<b>7.26</b>	<b>2.64</b>	<b>5.28</b>	<b>3.54</b>	<b>8.74</b>
Basic Shares Outstanding	212.70	218.94	258.35	269.94	278.97	289.29
Total Shares Outstanding	213.29	227.94	268.22	270.43	290.02	284.48
<b>EPS (diluted)</b>	<b>4.49</b>	<b>4.61</b>	<b>0.60</b>	<b>3.94</b>	<b>2.72</b>	<b>6.85</b>
Diluted Shares Outstanding	217.54	223.59	264.62	274.78	282.40	292.09
Total Shares Outstanding	213.29	227.94	268.22	270.43	290.02	284.48
Earnings Persistence	88.73	93.65	60.55	90.82	91.89	94.87
<b>Dividends per Share</b>	<b>2.64</b>	<b>2.92</b>	<b>3.00</b>	<b>3.08</b>	<b>3.16</b>	<b>3.32</b>
Payout Ratio	58.8	63.4	500.0	78.2	116.3	48.4
<b>EBITDA</b>						
<b>EBITDA</b>	<b>3,208</b>	<b>3,182</b>	<b>4,104</b>	<b>5,024</b>	<b>4,186</b>	<b>5,404</b>
EBIT	2,158	2,243	2,249	2,894	2,156	3,270
Depreciation & Amortization Expense	1,050	939	1,855	2,130	2,030	2,134

All figures in millions of U.S. Dollar except per share items.

Becton, Dickinson and Company (BDX)

\$262.04

Becton, Dickinson and Company  
BDX 075887109 2087807 NYSE Common stock  
Source: FactSet Fundamentals

	SEP '16	SEP '17	SEP '18	SEP '19	SEP '20	SEP '21
	Restated					
Assets						
Cash & Short-Term Investments	1,568	14,200	1,253	620	2,937	2,404
Cash Only	1,541	14,179	1,236	590	2,917	2,392
Total Short Term Investments	27	21	17	30	20	12
Short-Term Receivables	1,957	1,760	2,319	2,345	2,398	2,497
Accounts Receivables, Net	1,618	1,744	2,319	2,345	2,398	2,497
Accounts Receivables, Gross	1,685	1,793	2,394	2,420	2,478	2,573
Bad Debt/Doubtful Accounts	-67	-49	-75	-75	-80	-76
Other Receivables	339	16	0	0	0	0
Inventories	1,719	1,818	2,451	2,579	2,743	2,866
Finished Goods	1,129	1,234	1,644	1,717	1,806	1,823
Work in Progress	274	271	297	318	335	402
Raw Materials	316	313	510	544	602	641
Other Current Assets	1,123	855	1,388	1,120	891	1,071
Miscellaneous Current Assets	1,123	855	1,388	1,120	891	1,071
Total Current Assets	6,367	18,633	7,411	6,664	8,969	8,838
Net Property, Plant & Equipment	3,901	4,638	5,375	5,659	6,341	6,839
Property, Plant & Equipment - Gross	8,419	9,389	10,485	11,128	12,337	13,388
Buildings	2,397	2,496	2,724	2,842	3,082	3,264
Land & Improvements	151	146	173	164	166	137
Machinery & Equipment	5,749	6,584	7,405	7,932	8,454	9,301
Other Property, Plant & Equipment	122	163	183	190	217	240
Operating Lease Right-of-Use Assets					418	446
Accumulated Depreciation	4,518	4,751	5,110	5,469	5,996	6,549
Total Long-Term Investments	796	38	0	0	0	0
Long-Term Note Receivable	796	38				
Intangible Assets	13,770	13,456	40,041	38,354	37,433	36,684
Goodwill	7,419	7,563	23,600	23,376	23,620	23,901
Other Intangible Assets	6,351	5,893	16,441	14,978	13,813	12,783
Deferred Tax Assets						1,343
Other Assets	752	969	1,077	1,088	1,269	162
Tangible Other Assets	752	969	1,077	1,088	1,269	162
Total Assets	25,586	37,734	53,904	51,765	54,012	53,866
Liabilities & Shareholders' Equity						
Current						
ST Debt & Curr. Portion LT Debt	1,001	203	2,601	1,309	813	626
Accounts Payable	665	797	1,106	1,092	1,355	1,793
Income Tax Payable	274	176	343	140	144	176
Other Current Liabilities	2,460	2,166	3,166	3,114	3,524	4,031
Accrued Payroll	696	773	910	987	993	1,214
Miscellaneous Current Liabilities	1,764	1,393	2,256	2,127	2,531	2,817
Total Current Liabilities	4,400	3,342	7,216	5,655	5,836	6,626
Long-Term						
Long-Term Debt	10,550	18,667	18,894	18,081	17,560	17,454
Long-Term Debt excl Lease Obligations	10,550	18,667	18,894	18,081	17,224	17,110
Capital and Operating Lease Obligations	0	0	0	0	336	344
Provision for Risks & Charges	1,319	1,168	1,056	1,272	1,435	1,228
Deferred Tax Liabilities						2,693
Other Liabilities	1,684	1,609	5,744	5,676	5,416	2,188
Other Liabilities (excl. Deferred Income)	1,684	1,609	5,744	5,676	5,416	2,188
Total Liabilities	17,953	24,786	32,910	30,684	30,247	30,189
Equity						
Preferred Stock (Carrying Value)	0	2	2	2	2	2
Non-Redeemable Preferred Stock	0	2	2	2	2	2
Common Equity	7,633	12,946	20,992	21,079	23,763	23,675
Common Stock Par/Carry Value	333	347	347	347	365	365
Additional Paid-In Capital/Capital Surplus	4,693	9,619	16,179	16,270	19,270	19,272
Retained Earnings	12,727	13,109	12,594	12,912	12,791	13,826
Cumulative Translation Adjustment/Unrealized For. Exch. Gain	-1,011	-1,001	-1,162	-1,256	-1,416	-1,294
Unrealized Gain/Loss Marketable Securities	0	0	0	0	0	0
Other Appropriated Reserves	-897	-701	-723	-1,004	-1,109	-771
Treasury Stock	-8,212	-8,427	-6,243	-6,190	-6,138	-7,723
Total Shareholders' Equity	7,633	12,948	20,994	21,081	23,765	23,677
Total Equity	7,633	12,948	20,994	21,081	23,765	23,677
Total Liabilities & Shareholders' Equity	25,586	37,734	53,904	51,765	54,012	53,866
Per Share						
Book Value per Share	35.79	56.80	78.26	77.95	81.94	83.22
Tangible Book Value per Share	-28.77	-2.24	-71.02	-63.88	-47.14	-45.73

All figures in millions of U.S. Dollar except per share items.

Becton, Dickinson and Company (BDX)

\$262.04

Becton, Dickinson and Company

BDX 075887109 2087807 NYSE Common stock

Source: FactSet Fundamentals

	SEP '16	SEP '17	SEP '18	SEP '19	SEP '20	SEP '21
	Restate					
Operating Activities						
Net Income / Starting Line	976.0	1,100.0	311.0	1,233.0	874.0	2,092.0
Depreciation, Depletion & Amortization	1,114.0	1,088.0	1,978.0	2,253.0	2,154.0	2,273.0
Depreciation and Depletion	516.0	523.0	681.0	712.0	727.0	
Amortization of Intangible Assets	598.0	565.0	1,297.0	1,541.0	1,427.0	
Deferred Taxes & Investment Tax Credit	-426.0	-236.0	-240.0	-381.0	-302.0	-304.0
Deferred Taxes	-426.0	-236.0	-240.0	-381.0	-302.0	-304.0
Other Funds	496.0	969.0	-81.0	594.0	700.0	252.0
Funds from Operations	2,160.0	2,921.0	1,968.0	3,699.0	3,426.0	4,313.0
Changes in Working Capital	399.0	-371.0	897.0	-369.0	113.0	334.0
Receivables	-77.0	-79.0	-170.0	-51.0	-48.0	-95.0
Inventories	69.0	-46.0	246.0	-149.0	-125.0	-104.0
Other Assets/Liabilities	407.0	-246.0	821.0	-169.0	286.0	533.0
Net Operating Cash Flow	2,559.0	2,550.0	2,865.0	3,330.0	3,539.0	4,647.0
Investing Activities						
Capital Expenditures	-718.0	-727.0	-895.0	-957.0	-810.0	-1,231.0
Capital Expenditures (Fixed Assets)	-693.0	-727.0	-895.0	-957.0	-810.0	-1,231.0
Capital Expenditures (Other Assets)	-25.0	0.0	0.0	0.0	0.0	0.0
Net Assets from Acquisitions	0.0	-174.0	-15,155.0	0.0	-164.0	-508.0
Sale of Fixed Assets & Businesses	158.0	165.0	534.0	477.0	0.0	0.0
Purchase/Sale of Investments	-1.0	13.0	0.0	0.0	0.0	0.0
Purchase of Investments	1.0	0.0	0.0	0.0	0.0	0.0
Sale/Maturity of Investments	0.0	13.0	0.0	0.0	0.0	0.0
Other Funds	-108.0	-160.0	-217.0	-261.0	-258.0	-142.0
Other Uses	-108.0	-160.0	-217.0	-261.0	-258.0	-142.0
Other Sources		0.0	0.0	0.0	0.0	0.0
Net Investing Cash Flow	-669.0	-883.0	-15,733.0	-741.0	-1,232.0	-1,881.0
Financing Activities						
Cash Dividends Paid	-562	-677	-927	-984	-1,026	-1,048
Common Dividends	-562	-677	-927	-984	-1,026	-958
Preferred Dividends	0					-90
Change in Capital Stock	-32	4,607	0	0	2,917	-1,750
Repurchase of Common & Preferred Stk.	-32	-220	0	0	0	-1,750
Sale of Common & Preferred Stock	0	4,827	0	0	2,917	0
Proceeds from Sale of Stock	0	4,827	0	0	2,917	0
Issuance/Reduction of Debt, Net	-1,252	7,282	1,090	-2,035	-1,760	-243
Change in Current Debt	-500	-200	0	485	-485	0
Change in Long-Term Debt	-752	7,482	1,090	-2,520	-1,275	-243
Issuance of Long-Term Debt	0	11,462	5,086	2,224	3,389	4,869
Reduction in Long-Term Debt	-752	-3,980	-3,996	-4,744	-4,664	-5,112
Other Funds	85	-235	-221	-204	-109	-265
Other Uses	0	-235	-221	-205	-109	-265
Other Sources	85	0	0	1	0	0
Net Financing Cash Flow	-1,761	10,977	-58	-3,223	22	-3,306
All Activities						
Exchange Rate Effect	-12.0	-6.0	-17.0	-12.0	-3.0	15.0
Miscellaneous Funds	0.0	0.0	0.0	0.0	0.0	0.0
Net Change in Cash	117.0	12,638.0	-12,943.0	-646.0	2,326.0	-525.0
Free Cash Flow	1,866.0	1,823.0	1,970.0	2,373.0	2,729.0	3,416.0
Free Cash Flow per Share	8.6	8.2	7.4	8.6	9.7	11.7
Free Cash Flow Yield (%)	4.8	4.2	2.9	3.4	4.2	4.8

All figures in millions of U.S. Dollar except per share items.

**BDX-US****Sales**

	SEP '12	SEP '13	SEP '14	SEP '15	SEP '16	SEP '17	SEP '18	SEP '19	SEP '20	SEP '21
	366 Days	365 Days	365 Days	365 Days	366 Days	365 Days	365 Days	365 Days	366 Days	365 Days
Total	7,708	8,054	8,445	10,282	12,483	12,093	15,983	17,290	17,117	20,248
Medical	4,091	4,306	4,573	6,460	8,654	8,105	8,616	9,064	8,680	9,479
Life Sciences	-	-	-	3,822	3,829	3,988	4,330	4,300	4,675	6,530
Interventional	-	-	-	-	-	-	3,037	3,926	3,762	4,239
<b>Historical Segments</b>	<b>3,618</b>	<b>3,748</b>	<b>3,872</b>	-	-	-	-	-	-	-
Diagnostics	2,538	2,646	2,713	-	-	-	-	-	-	-
Biosciences	1,080	1,102	1,159	-	-	-	-	-	-	-

All figures in millions of U.S. Dollar